<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">HEINICKE, T.</style></author><author><style face="normal" font="default" size="100%">WARDELMANN, E.</style></author><author><style face="normal" font="default" size="100%">SAUERBRUCH, T.</style></author><author><style face="normal" font="default" size="100%">TSCHAMPA, H.J.</style></author><author><style face="normal" font="default" size="100%">GLASMACHER, A.</style></author><author><style face="normal" font="default" size="100%">PALMEDO, H.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Very Early Detection of Response to Imatinib Mesylate Therapy of Gastrointestinal Stromal Tumours Using 18Fluoro-Deoxyglucose-Positron Emission Tomography</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2005-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4591-4594</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><issue><style face="normal" font="default" size="100%">6C</style></issue><abstract><style  face="normal" font="default" size="100%">Aim: To investigate whether 18F-FDG-PET allows early assessment of response to imatinib mesylate in GIST patients. Patients and Methods: Five gastrointestinal stromal tumour (GIST) patients and one patient with a KIT-positive small cell cancer were studied. Treatment consisted of 400 mg imatinib mesylate daily. 18F-deoxyglucose-positron emission tomography (18F-FDG-PET) scans were done before and one week after starting imatinib mesylate therapy. Results: Metabolic responses were detected after only one week of therapy in all GIST patients (four partial and one complete response). The mean decrease of the standardised uptake value was 60% (range 43 to 77%). In contrast, the tumour of the non-GIST patient was metabolically stable. Four of the 5 GIST patients achieved a partial response on CT after a mean duration of 23 weeks (range 6 to 48 weeks). Conclusion: 18F-FDG-PET is a valuable method for the detection of response to imatinib mesylate in patients with KIT-positive tumours as early as one week after starting therapy. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>